Bendamustine

CAT: 0804-HY-13567-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-13567-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties[1].
CAS Number
[16506-27-7]
Product Name Alternative
SDX-105 (free base)
UNSPSC
12352005
Hazard Statement
H301, H311, H331, H341
Target
Apoptosis; DNA Alkylator/Crosslinker
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Bendamustine.html
Purity
98.0
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C
Molecular Formula
C16H21Cl2N3O2
Molecular Weight
358.26
Precautions
H301, H311, H331, H341
References & Citations
[1]Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14 (1) :309-17.|[2]Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25 (5) :1108-17.|[3]Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167 (4) :881-91.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Leukemia. 2023 Nov;37 (11) :2221-2230.|Cell Rep Med. 2025 Apr 2:102053.|J Biomed Res. 2017 0 (0) : 1-12.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Patent. US20160222465A1.

Popular Products